WIRE — The brokerage retained its underperform rating and Rs 326 target price, saying the recent block deal does not materially change Biocon's long-term earnings outlook.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.